Helixmith

At a glance

Helixmith filed 20 disclosures in the last 12 months, including 2 5% holder. The most recent key filing was on May 4.

Revenue for 2025 was ₩2.6B, down 47.8% on 2024. It made an operating loss of ₩9.9B. Debt was 1% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.4B and operating loss of ₩4.4B.

The 2025 annual report lists 44 employees with an average tenure of 3.9 years and average pay of ₩54.4M. Its 10 directors and auditors were paid ₩111.6M each on average. It paid no cash dividend for 2025. (주)바이오솔루션 and related parties held 18.23% at year end.

From the 2025 annual report

Staff: 44 (26 men, 18 women), of whom 5 on fixed-term contracts. Total pay for the year: ₩2.4B. Directors and auditors: 10, paid ₩1.1B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)바이오솔루션 holds 18.23%; with 0 related parties the group holds 18.23% of common shares at year end.

Auditor: 삼화회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary